• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Singapore develops its first cancer drug

Singapore develops its first cancer drug

March 17, 2011
CenterWatch Staff

Singapore has developed its first cancer drug, SB-939, from two Singapore-based cancer institutes and a biotechnology company, S*BIO, according to Channel News Asia.   The Singapore National University Cancer Institute, the Cancer Institute of Singapore and S*BIO have collaborated for the phase I trials.

For over a year, the drug was administered orally to 30 cancer patients three times a week.  Of these, 24 tolerated the drug well and four showed better than expected tumor growth control.

Associate Professor Goh Boon Cher, senior consultant of the Singapore National University Cancer Institution, said, "the drug actually works by causing cancer cells to die preferentially over the normal cells. So there is some selective advantage to killing cancer."

"The main side effect was tiredness and some patients who had a lower platelet count. There were some insignificant abnormalities in electrocardiograms. In general, these side effects were tolerable, reversible and did not harm the patients,” said Goh.

Phase I assessed the safety and tolerability of the drug and served to set the dosage for the phase II trials.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing